



HAL
open science

Ketone Bodies Promote Amyloid- β 1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model

Romain Versele, Mariangela Corsi, Andrea Fuso, Emmanuel Sevin, Rita Businaro, Fabien Gosselet, Laurence Fenart, Pietra Candela

► **To cite this version:**

Romain Versele, Mariangela Corsi, Andrea Fuso, Emmanuel Sevin, Rita Businaro, et al.. Ketone Bodies Promote Amyloid- β 1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model. *International Journal of Molecular Sciences*, 2020, 21 (3), pp.934. 10.3390/ijms21030934 . hal-02538226

HAL Id: hal-02538226

<https://univ-artois.hal.science/hal-02538226v1>

Submitted on 31 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Article

Ketone Bodies Promote Amyloid- β_{1-40} Clearance in a Human in Vitro Blood–Brain Barrier Model

Romain Versele ¹, Mariangela Corsi ^{1,2}, Andrea Fuso ³, Emmanuel Sevin ¹, Rita Businaro ², Fabien Gosselet ¹, Laurence Fenart ^{1,†} and Pietra Candela ^{1,†,*}

¹ Laboratoire de la Barrière Hémato-Encéphalique (LBHE), UR 2465, Université d'Artois, F-62300 Lens, France; romain_versele@ens.univ-artois.fr (R.V.); mariangela_corsi@libero.it (M.C.); emmanuel.sevin@univ-artois.fr (E.S.); fabien.gosselet@univ-artois.fr (F.G.); laurence.tilloy@univ-artois.fr (L.F.)

² Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy; rita.businaro@uniroma1.it

³ Department of Experimental Medicine, Sapienza University of Rome, Dip. di Chirurgia “P. Valdoni”, Via A. Scarpa 16, 00161 Rome, Italy; Andrea.Fuso@uniroma1.it

* Correspondence: pietra.candela@univ-artois.fr

† These authors contributed equally to this work.

Received: 17 January 2020; Accepted: 29 January 2020; Published: 31 January 2020



Abstract: Alzheimer’s disease (AD) is characterized by the abnormal accumulation of amyloid- β (A β) peptides in the brain. The pathological process has not yet been clarified, although dysfunctional transport of A β across the blood–brain barrier (BBB) appears to be integral to disease development. At present, no effective therapeutic treatment against AD exists, and the adoption of a ketogenic diet (KD) or ketone body (KB) supplements have been investigated as potential new therapeutic approaches. Despite experimental evidence supporting the hypothesis that KBs reduce the A β load in the AD brain, little information is available about the effect of KBs on BBB and their effect on A β transport. Therefore, we used a human in vitro BBB model, brain-like endothelial cells (BLECs), to investigate the effect of KBs on the BBB and on A β transport. Our results show that KBs do not modify BBB integrity and do not cause toxicity to BLECs. Furthermore, the presence of KBs in the culture media was combined with higher MCT1 and GLUT1 protein levels in BLECs. In addition, KBs significantly enhanced the protein levels of LRP1, P-gp, and PICALM, described to be involved in A β clearance. Finally, the combined use of KBs promotes A β efflux across the BBB. Inhibition experiments demonstrated the involvement of LRP1 and P-gp in the efflux. This work provides evidence that KBs promote A β clearance from the brain to blood in addition to exciting perspectives for studying the use of KBs in therapeutic approaches.

Keywords: blood–brain barrier; Alzheimer’s disease; ketone bodies; β -hydroxybutyrate; acetoacetate; amyloid- β peptide

1. Introduction

Affecting more than 46 million individuals worldwide, Alzheimer’s disease (AD) is now considered to be the most common cause of dementia in the elderly population (World Health Organization (WHO)), with an increase of 7.7 million new cases every year. The pathological features of AD include intracellular neurofibrillary tangles (reviewed in [1]) and the accumulation of amyloid- β peptides (A β) forming senile plaques in brain parenchyma as well as in the walls of intracerebral microvessels [2]. A β peptides are ~4 kDa proteins comprising 36–48 aa. Around brain microvessels, the most abundant form of A β comprises 40 aa (A β_{1-40} ~80–90%) [3]. Among several independent mechanisms for clearing

these A β peptides from the central nervous system (CNS), the bidirectional transport of A β across the blood–brain barrier (BBB) plays a major role [4–6].

The BBB is a physiological barrier histologically formed by endothelial cells (ECs) lining the brain microvessels [7,8]. This physical barrier strictly controls the exchange of molecules between the brain and the blood in order to protect the CNS and to maintain its functioning and homeostasis [8,9]. ECs express specific sets of receptors and transporters at the apical side (blood side) and basolateral side (brain side), regulating the brain's nutrient supply. Glucose transporter 1 (GLUT1) and monocarboxylate transporter 1 (MCT1) are respectively involved in importing glucose and ketone bodies (KBs) into the brain. Furthermore, ECs express several receptors and transporters involved in the bidirectional soluble A β exchange across the BBB. Low-density lipoprotein receptor-related protein 1 (LRP1) is involved in A β efflux (brain to blood) [10,11], while the receptor for advanced glycation endproducts (RAGE) is implicated in A β influx (blood to brain) [12,13]. Moreover, several members of the ATP-binding cassette (ABC) family, such as ABCB1 (also known as P-glycoprotein (P-gp)) and ABCG2 (also known as breast cancer resistance protein (BCRP)), are involved in A β efflux and limiting A β influx [13,14]. Dysregulation of their expression may trigger the progressive cerebral and vascular accumulation of A β , as demonstrated in animal studies and clinical research [5,6,15]. Notably, the downregulation of LRP1 and P-gp during AD is one of the key events leading to A β accumulation by decreasing A β clearance from the brain [11,16]. These two proteins have been functionally linked to phosphatidylinositol-binding clathrin assembly protein (PICALM) [17], which is identified as a genetic risk factor for AD [18,19]. Therefore, increasing the clearance of A β across the BBB via the induction of P-gp or/and LRP1 expression, and consequently PICALM, may be an effective strategy to protect the brain from the accumulation of A β [20] and prevent AD onset. One of the new AD treatments currently under development is the ketogenic diet (KD) [21–24]. KD is characterized by a nutrient intake that is very poor in carbohydrates and high in fatty acids [25]; hence, it produces much of the same physiological effects of low food intake (i.e., fasting) [26,27] and promotes the production of KBs (in liver mitochondria), β -hydroxybutyrate (β HB) and acetoacetate (AcAc) in particular. During starvation or consumption of a KD, the relative level of glucose in the plasma declines, and that of KBs increases [25,27]. The KBs are then utilized by extrahepatic tissues—including the brain—as an energy source [28,29]. Indeed, KBs are transported across the BBB via MCT1 and consumed by the brain as the major energy source when glucose is limited [30,31]. Despite experimental and clinical evidence supporting the protective effect of a KD against AD [32,33] through reduced A β deposition and improved learning memory [34–37], little is known about the impact of this diet on BBB function.

Notably, the way in which a KD counteracts amyloid deposition remains unstudied. Therefore, we hypothesized that a KD and, in particular, KBs, act at the BBB level to promote amyloid elimination from the brain. Hence, we investigated the effects of relevant KBs using a human in vitro BBB model. Our data show that KBs do not modify the BBB integrity but impact the expression of proteins involved in the transport of KBs and glucose (MCT1 and GLUT1, respectively) as well as A β _{1–40} peptide transport across the BBB. In particular, KBs enhanced protein expression of LRP1, P-gp, and PICALM at the BBB level. The combined use of KBs (AcAc and β HB) improved basolateral-to-apical A β _{1–40} peptide transport through the BBB. Inhibition studies also demonstrated the functional involvement of LRP1 and P-gp in the clearance of A β .

2. Results

2.1. KBs do not Affect the Viability and Integrity of BLECs

To determine the effects of KBs on the BBB, we used a human in vitro BBB model consisting of co-cultivated endothelial cells derived from umbilical cord blood CD34⁺ stem cells with brain pericytes [38,39]. These cells were seeded on a matrigel-coated insert that separates two compartments, the apical compartment with endothelial cells (blood side) and the basolateral compartment with the

pericytes (brain side) (Figure 1A). After 5 days of culture, the endothelial cells showed BBB properties similar to those observed in vivo, and were named brain-like endothelial cells (BLECs).




Figure 1. The effect of KBs on BLEC permeability. (A) Schematic representation of the human in vitro BBB model used for the KB study. This model is composed of an apical compartment in the filter containing endothelial cells and a basolateral compartment in the well with brain pericytes. After 5 days of co-culture, BLECs were incubated with various concentrations of KBs, AcAc, or βHB alone (5–20 mM) or in combination (20 mM AcAc/20 mM βHB) for 48 h. Following KB treatment, the BLECs on the insert were transferred to a new plate for experiments. (B) The effects of KBs on cell viability were analyzed by MTT assay. (C) BLEC monolayer integrity was determined by measuring the endothelial lucifer yellow permeability (Pe_{LY}). Each bar represents the mean \pm SEM relative to the control conditions ($Pe_{LY} = 0.92 \pm 0.03 \times 10^{-3} \text{ cm}\cdot\text{min}^{-1}$). The results are representative of three independent experiments performed in triplicate (** $p < 0.001$). (D) Associated tight junction protein ZO-1 (green) and tight junction protein claudin-5 (red) staining were stained using immunofluorescence. Interruptions in the staining are indicated by white arrows. Nuclei were stained with Hoechst reagent and appear in blue. Scale bar: 50 μm .

BLEC viability was determined using an MTT assay after 48 h of exposure to different KB concentrations in the apical compartment (corresponding to the blood side). The results shown in Figure 1B reveal no difference in viability between KB-treated cells and control (non-treated) cells. Based on these results, 20 mM AcAc, 20 mM βHB, and 20 mM AcAc/20 mM βHB (referred to as the “ratio” in the rest of the paper) were selected as the treatment conditions for further experiments. Since the BBB integrity is of primary importance for maintaining correct brain functioning, we assessed the

impact of KBs on BBB permeability. To this end, BLECs were incubated with KBs for 48 h. To exclude the possibility that BLECs were not responsive to the damage possibly induced by KBs, we treated the human *in vitro* BBB model with mannitol, which is known to disrupt the BBB [40]. BBB permeability was checked by measuring the speed of diffusion of the small paracellular marker Lucifer Yellow (LY; ~400 Da) across the BLEC monolayer to determine the endothelial permeability of Lucifer Yellow (P_{eLY}). As shown in Figure 1C, no significant differences in P_{eLY} values were observed for any of the KBs tested compared to the control, except for the 20 mM of AcAc treatment where a decrease in P_{eLY} was observed (14.6%; p -value ≤ 0.0001). As expected, a huge and significant increase in P_{eLY} values for the mannitol treatment compared to non-treated cells (620.6%; p -value ≤ 0.0001) was observed. In addition, immunofluorescence analysis of tight junction proteins ZO-1 and claudin-5 confirmed that KBs did not affect the intercellular contacts between endothelial cells (Figure 1D). By contrast, mannitol treatment caused an interruption in the staining for ZO-1 and claudin-5 protein, indicating an alteration in the tight junction network (Figure 1D, basal lane).

Overall, our results indicate that KBs do not cause toxicity to BLECs and do not modify BBB integrity, at least in the tested concentration range.

2.2. KBs Increase MCT1 and GLUT1 Protein Levels in BLECs

During starvation, when glucose levels decline and blood KB concentrations increase, an increase in GLUT1 and MCT1 expression is observed in neuronal tissues [41,42]. Therefore, we wanted to determine whether MCT1 and GLUT1 at the level of BLECs would be modulated by KB treatment. First, glucose and β HB concentrations were analyzed in the culture media of our *in vitro* BBB model in the presence of different KBs amounts over 48 h, with untreated cells used for comparison. The concentration of AcAc was not measured as we lacked a method for AcAc detection. As shown in Figure 2A, a decrease in glucose concentration, from 1 to 0.2 g·L⁻¹ (detection threshold of Precision Xtra meter), was observed in the apical compartment. Similar results were observed in the basolateral compartment (data not shown). β HB concentrations were similarly measured in (i) the apical compartment, (ii) BLECs, and (iii) the basolateral compartment after 48 h (Figure 2B).

The stability of the β HB at 37 °C and at 5% CO₂ was checked in the culture media over 48 h (see the methods section). After incubation with 20 mM β HB in the BBB model, we observed 42.9% of the total amount of β HB in the apical compartment, 2.4% in BLECs, and 33.3% in the basolateral compartment. Hence, 21.4% of the initially added β HB was not detectable. The results with 20 mM AcAc/20 mM β HB (ratio condition) were similar to those using 20 mM β HB (Figure 2B). The latter results demonstrate that under experimental conditions in which the glucose levels fall, KBs were partially catabolized by BLECs and were still present in the culture medium 48 h after treatment. Under the same conditions, we examined the effects of KBs on the MCT1 and GLUT1 protein levels in BLECs. First, immunofluorescence staining demonstrated that both MCT1 and GLUT1 were expressed in untreated BLECs (Figure 2C). Next, quantification of MCT1 and GLUT1 was performed using Western blot assays. After 48 h of KB treatments, MCT1 protein levels significantly increased in AcAc, β HB, and the ratio condition by 35.9% (p -value = 0.0247), 24.9% (p -value = 0.0455), and 66.5% (p -value = 0.0062), respectively, in the BLECs as compared to the control (Figure 2D). In the same way, GLUT1 protein levels increased significantly in β HB and in the ratio condition by 51.9% (p -value = 0.0027) and 39.8% (p -value = 0.0047), respectively.

Overall, our results demonstrate that when glucose levels fall, β HB is stable and is still present in the culture medium and inside the BLECs after 48 h of treatment. In addition, the presence of KBs in the culture medium was associated with higher MCT1 and GLUT1 protein levels in BLECs, which corresponds with previous *in vivo* results.




Figure 2. Effect of KBs on the human in vitro BBB model. (A) BLECs were incubated with various concentrations of KBs for 48 h: 20 mM AcAc, 20 mM β HB, or ratio (20 mM AcAc/20 mM β HB). The glucose concentration was measured in the apical compartment every 8 h. (B) The β HB concentration was measured in the apical and basolateral compartments and in BLECs. The data are represented as mean \pm SEM obtained from three independent experiments. (C) The presence of MCT1 (green) and GLUT1 (red) in the BLECs was performed using immunostaining. Nuclei were stained with Hoechst reagent, and appear in blue. Scale bar: 50 μ m. (D) The effects of KBs on MCT1 and GLUT1 protein levels were analyzed by Western blot. The protein level was normalized using β -actin. The protein data represent the mean \pm SEM obtained from at least three independent experiments relative to control conditions (* $p < 0.05$, ** $p < 0.01$). (E) The images are representative of at least three independent experiments.

2.3. KBs Modify the Levels of Proteins Involved in $A\beta_{1-40}$ Peptide Transport Across the BBB

In addition to the effect of KBs on MCT1 and GLUT1, we assessed the protein levels of receptors and transporters involved in the apical-to-basolateral and basolateral-to-apical transport of $A\beta_{1-40}$ peptide in BLECs following KB treatment. We showed that the protein levels of P-gp were significantly increased in AcAc and in the ratio treatments by 47.9% (p -value = 0.0024) and 112.0% (p -value \leq 0.0001), respectively, compared to the control (Figure 3A). BCRP protein levels were not significantly different (Figure 3B). Interestingly, LRP1 protein levels were significantly upregulated in the presence of β HB and in the ratio treatments by 109.3% (p -value = 0.0079) and 54.5% (p -value = 0.0317), respectively, compared to the control (Figure 3C). RAGE protein levels were not affected by any of the KBs treatments (Figure 3D). We also investigated whether KBs affected the levels of PICALM protein, which has been described to interact with LRP1 and P-gp transporters [17,43]. As observed in Figure 3E, PICALM protein levels increased in BLECs upon exposure to β HB and ratio by 39.1% (p -value = 0.0009) and 39.4% (p -value = 0.0031), respectively, compared to the control.




Figure 3. Effects of KBs on the protein expression of actors involved in A β peptide transport in BLECs. The protein levels of (A) P-gp, (B) BCRP, (C) LRP1, (D) RAGE, and (E) PICALM were quantified using Western blot. The data were normalized using β -actin. The results represent the mean \pm SEM obtained from at least three independent experiments relative to the control conditions (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). (F) The images are representative of at least three independent experiments.

These data indicate that KBs are able to modulate LRP-1, P-gp, and PICALM protein levels in BLECs. These three proteins are the major players involved in A β peptide efflux across the BBB.

2.4. KBs Increase Basolateral-to-Apical A β Peptide Transport Through the BBB with the Involvement of LRP-1 and P-gp

We hypothesized that KB treatment could be associated with a higher clearance of A β peptide through the BBB. Thus, the apical-to-basolateral (influx) and basolateral-to-apical (efflux) A β_{1-40} Cy5 peptide transport across BLECs was assessed as previously described [13,39,44]. For these experiments, we used A β_{1-40} , since this is the most abundant amyloid peptide found in brain microvessels [45]. As a control in these experiments, the apical-to-basolateral and basolateral-to-apical transport of inulin was determined across BLECs. Inulin was used as a non-specific transport marker, as previously described [13,46]. As shown in Figure 4B, the apical-to-basolateral transport of the A β_{1-40} Cy5 peptide was not affected by the presence of KBs. In the same way, the values for [3 H]inulin transport did not differ significantly in the presence of KBs, except for the AcAc condition, where a slight decrease was observed (12.9%, p -value = 0.0005) (Figure 4B).




Figure 4. Effect of KBs on A β transport across BBB. (A) Schematic representation of the human in vitro BBB model used for (A) apical-to-basolateral (red arrow) and (C) basolateral-to-apical (green arrow) A β transport. After 48 h of treatment with KBs, A β_{1-40} Cy5 or [3 H]inulin was added to the (B) apical compartment or (D) basolateral compartment, incubated for 30 min, and permeability was then assessed. The data represent the mean \pm SEM obtained from at least three independent experiments relative to the control conditions, each of which was performed in triplicate (***) $p < 0.001$.

Only the basolateral-to-apical transport of A β_{1-40} Cy5 (Figure 4D) was significantly higher in the ratio treatment relative to the control condition (by 52.0%, p -value ≤ 0.0001), suggesting that KBs are able to partly enhance basolateral-to-apical A β peptide transport. In fact, no significant difference in A β_{1-40} Cy5 transport was observed in the other KB conditions. The values for [3 H]inulin transport did not differ significantly in the presence of KBs (Figure 4D), confirming that A β transport across the BBB is regulated by specific mechanisms. In light of our previous results (Figure 3A,C) after 48 h of KB treatments (ratio), the transport of A β_{1-40} Cy5 or [3 H]inulin was studied in the presence or in the absence of two standard inhibitors for LRP1 and P-gp [11,47–49], the receptor-associated protein (RAP) (in the basolateral side) or elacridar (in the apical side), respectively. As shown in Figure 5C, the increased basolateral-to-apical of A β_{1-40} Cy5 peptide transport was abolished in the presence of RAP or elacridar. By contrast, the basolateral-to-apical transport of [3 H]inulin was not affected by RAP or elacridar. The treatments had no significant effect on BBB permeability (data not shown), confirming that the BBB model was not compromised by KBs.

These observations suggest that only the combination of the two KBs was able to increase basolateral-to-apical transport of A β peptide. The use of LRP1 and P-gp inhibitors demonstrated the functional involvement of LRP1 and P-gp activity in the efflux of A β peptide across the BBB.




Figure 5. Involvement of LRP1 and P-gp in basolateral-to-apical transport of Aβ₁₋₄₀Cy5 peptide after ratio KB treatment. (A) Schematic representation of the human in vitro BBB model used for basolateral to-apical Aβ transport (green arrow) in the presence of (A) LRP1 or (B) P-gp inhibitors, respectively RAP (red ban symbol) or elacridar (orange ban symbol). (C) Aβ₁₋₄₀Cy5 or [³H]inulin basolateral-to-apical transport was performed with RAP or elacridar. The data represent the mean ± SEM obtained from at least three independent experiments relative to the control conditions, each of which was performed in triplicate (***) $p < 0.001$.

3. Discussion

For a few years now, there has been an increased focus on the role of the transport of Aβ peptides across the blood–brain barrier (BBB) [4,50,51]. It appears that increasing the clearance or reducing the entry of Aβ peptides in the brain could be a promising therapeutic approach for counteracting the pathogenic processes observed in AD [52]. In recent years, there has been mounting interest in the possible utilization of a ketogenic diet (KD) or ketone body (KB) supplementations in the treatment of AD [53,54]. On the basis of KBs' beneficial effects on the CNS, and the lack of published data on the BBB, we addressed the question of whether KBs could modulate the expression of receptors/transporters implicated in the transport of Aβ across the BBB and whether these changes could impact functional transport. To explore our hypothesis, we used a human in vitro BBB model composed of a co-culture of endothelial cells (derived from CD34⁺ cells) and brain pericytes [38]. This model has already been used to study the transport of several molecules, including Aβ [39], and represents a useful tool for deciphering the cellular and molecular mechanisms of this transport. Firstly, we examined the effect of KBs on cell viability and BBB integrity. No cell toxicity was observed in our model following 48 h of treatment with a range of AcAc or βHB concentrations (0–20 mM alone, or 20 mM AcAc/20 mM βHB). This is consistent with previous studies that showed 95% of cell viability when PC12 cells were exposed in 0–20 mM βHB [55], and in contrast with other studies that reported an increase in BBB integrity when mouse brain microvascular endothelial cells were exposed to increasing concentrations of either βHB or AcAc [56]. Our results further show that KBs do not modify BBB permeability and continuous tight junction networks at cellular borders. Interestingly, a decrease in Pe_{LY} was observed under treatment with AcAc. It is likely that AcAc could change some structural component of the BBB, and in doing so, reinforce the permeability of the barrier [57]. This possibility needs to be clearly addressed through further investigations. In the absence of cellular toxicity, we decided to conduct mechanistic studies using highest doses. The used concentrations are higher than would be expected

in vivo [25,58], but also shorter in duration than those used in vivo [59]. In addition, the choice is even more pertinent knowing that an alternative to the KD is the use of exogenous KBs and ketone sources [60]. These exogenous KBs induce a nutritional ketotic state similar to that derived from KD, resulting in elevated serum KBs, but are safer and more efficient [61,62]. Moreover, higher doses are possible [63]. Therefore, it is of great interest to carry out in vitro experiments with KBs at higher concentrations to assess their molecular effects on cells.

We showed that when the glucose concentration decreases, it fell rapidly from $1\text{g}\cdot\text{L}^{-1}$ (the normal approximate blood sugar levels found in vivo) to zero, while βHB was stable and still present in the culture medium and in endothelial cells (we found that 42.9% of the total amount of βHB was in the apical compartment ($\sim 8.5\text{ mM}$), 2.4% was in the BLEC ($\sim 0.5\text{ mM}$), and 33.3% ($\sim 6.6\text{ mM}$) was in the basolateral compartment). The presence of KBs both in the culture medium and in BLECs after 48 h of incubation corresponded with the higher levels of MCT1 and GLUT1 proteins observed in BLECs. These observations are in agreement with those published by others in which an increase of KBs in the blood following a KD was associated with higher MCT1 and GLUT1 expression in rat brain microvessels [64–67], and in contrast with other studies, which reported that a KD does not affect the expression of GLUT1 at the BBB level [68]. In addition, it has been shown that βHB is specifically able to enhance GLUT1 protein expression in mouse brain endothelial cells [69].

Previous reports have shown that the induction of ketosis in mouse and dog models led to reduced accumulation of $\text{A}\beta$ within the brain [37,70]. However, the way in which KBs are able to decrease the $\text{A}\beta$ burden has yet to be elucidated. For the first time, we demonstrated that KBs are able to modulate LRP-1, P-gp, and PICALM protein levels in BLECs. In particular, we showed that (i) the protein levels of P-gp were significantly increased in AcAc and in the ratio condition, (ii) LRP1 protein levels were significantly upregulated by both βHB and in the ratio condition, and, interestingly, that (iii) the PICALM protein level was induced in BLECs upon exposure to βHB and the ratio condition. Instead, the protein levels of RAGE and BCRP were not affected by the addition of KBs. These data are in line with previous studies demonstrating that nutritional factors (e.g., a cholesterol-enriched diet or oleocanthal (a phenolic secoiridoid component of extra virgin olive oil and vitamin B) exert neuroprotective effects against AD by impacting the transcription of genes coding for receptors and transporters involved in $\text{A}\beta$ transport across the BBB [71–74].

In particular, most of the cited papers showed that the upregulation of LRP1 and/or P-gp is essential for promoting $\text{A}\beta$ clearance across the BBB [75]. According to these results, we also demonstrated the marked elevation of basolateral-to-apical $\text{A}\beta_{1-40}$ Cy5 transport in the presence of KBs in the ratio condition. In addition, using our BBB model, we confirmed that these proteins are implicated in the efflux of $\text{A}\beta$ peptide. Our experiments demonstrate that the presence of RAP (in the basolateral compartment) and elacridar (in the apical compartment) in the BBB model was associated with significantly lower basolateral-to-apical transport of $\text{A}\beta$. These observations agree with similar in vitro results obtained in mouse models and human endothelial cells showing that upregulation of LRP1 and P-gp promotes $\text{A}\beta$ clearance across the BBB [11,67,74,76]. It is now accepted that the concerted $\text{A}\beta$ clearance of LRP1 and P-gp is linked by PICALM. Indeed, using a transgenic mouse model, it was demonstrated that the reduction of PICALM expression aggravates $\text{A}\beta$ pathology [77]. Inversely, the presence of PICALM in brain endothelial cells is essential for the rapid LRP1/P-gp-mediated clearance across the BBB [17]. In line with these results, we also observed that KBs are able to enhance PICALM levels. Thus, enhanced LRP1 and P-gp efflux function by KBs could also be mediated, at least in part, by activating PICALM expression. The significance of inducing this pathway was previously reported in another study showing that PICALM deficiency in mice diminished $\text{A}\beta$ efflux across the BBB, whereas PICALM re-expression was necessary to reverse this mechanism [77]. According to the fundamental role of PICALM in the transcytosis of $\text{A}\beta$, it would be interesting to know whether KBs are able to regulate trafficking inside the cells. Future studies will address this question.

However, as already mentioned, it cannot be excluded that other receptors or transporters are involved in the clearance of $\text{A}\beta$ peptide [10]. For example, it has been shown that other ABC

transporters, such as BCRP, have an important role in A β clearance from the brain [13,14,78,79]. However, no changes were detected in the expression of BCRP after KB treatment. For this reason, the implication of BCRP in the basolateral-to-apical A β_{1-40} Cy5 transport was excluded.

On the other hand, no change in the apical-to-basolateral A β_{1-40} Cy5 transport was observed under our culture conditions, confirming that KBs have no modulating effect on RAGE protein expression. These data partially agree with those of Guo et al. showing that the active form of vitamin D (1,25-dihydroxyvitamin D₃) has an important role in increasing A β transport from the brain to the blood via the upregulation of LRP1 and the downregulation of RAGE [80]. Indeed, while the implication of RAGE to mediate the entry of circulating A β is undisputed [12,13,76], it is possible that not all exogenous molecules may be able to modulate the protein expression of this cellular receptor. In this sense, the ability of rifampicin and caffeine to induce LRP1 and P-gp expression in wild-type C57BL/6 mice was recently demonstrated, while the treatments had no effect on RAGE expression in microvessels [75].

Interestingly, only a combination of KBs markedly increased basolateral-to-apical A β_{1-40} Cy5 transport. This indicates that the combined effects of the two KBs are more efficient or different than the effect elicited by each KB. Previous *in vitro* studies have already shown a different mechanism of action of AcAc and β HB. For example, using mouse brain microvascular-derived endothelial cells, it was demonstrated that AcAc and β HB differentially regulate the permeability of the BBB [56]. AcAc but not β HB stimulates the production of the vasoconstrictor endothelin-1. By contrast, β HB—but not AcAc—increases the synthesis of vascular endothelial growth factor (VEGF), a potent modulator of vascular permeability [56]. Moreover, Cheng et al. reported that AcAc and β HB have opposite effects on human endothelial cell viability, with AcAc inhibiting and β HB promoting cell proliferation [81]. More recently, Kanikarla-Marie and Jain reported that unlike β HB, high concentrations of AcAc intensify endothelial cell oxidative stress [82], inducing TNF α and MCP-1 expression as well as ROS accumulation [83]. Therefore, in accordance with our *in vitro* results, it is quite possible that the effects of the two KBs are synergistic and different than the effects of the KBs in isolation, highlighting the importance of studying both their separate and combined effects on cells. Increasing evidence indicates that alterations in DNA profiles can lead to changes in gene expression [84,85]. Knowing that KBs and, in particular, β HB are specific inhibitors of class I histone deacetylases (HDACs), it is likely that KBs provoke HDAC inhibition, which increases histone acetylation and thereby induces transcriptomic and epigenetic modifications at the BBB level, including the transport of Alzheimer's-associated peptides, such as amyloid. Future studies are needed to determine whether KBs can affect epigenetic and molecular events in the brain and in particular, at the BBB level.

In conclusion, this work provides evidence that KBs are not toxic on BLECs and can promote A β_{1-40} transendothelial transport (efflux) via their ability to enhance the function of LRP1 and P-gp transporter (and PICALM), which are responsible for A β clearance. These results may explain the recovery of cognitive functions observed in animal models as well as in patients. Moreover, the increased A β_{1-40} transendothelial transport detected in BLECs in the presence of 20 mM β HB/20 mM AcAc suggests that the KBs' combined effect is greater than the individual effects. Our work provides exciting perspectives for studying the KBs as a non-pharmacological means of targeting A β clearance and developing new therapeutic strategies in modulating the progression of AD.

4. Materials and Methods

4.1. Materials

Endothelial cell medium (ECM; Sciencell, USA) supplemented with 5% heat-inactivated fetal calf serum (FCS, GIBCO, Life Technology SAS, Saint Aubin, France), 50 μ g·mL⁻¹ gentamicin (Biochrom GmbH, Germany), and 0.5% endothelial cell growth factor (Sciencell, USA) (ECM-5) was prepared and stored at 4 °C for a maximum of one week. Beta-hydroxybutyric acid (β HB, as DL- β -hydroxybutyric acid sodium salt) and acetoacetate (AcAc, as lithium acetoacetate) were purchased from Sigma-Aldrich

(Lyon, France), dissolved in culture medium (according to the manufacturer's instructions), and stored at -20°C . Lucifer yellow (LY, Lucifer Yellow CH dilithium salt) and human serum albumin (HSA) were purchased from Sigma-Aldrich. $[^3\text{H}]$ inulin ($1.25\text{ Ci. mmol}^{-1}$) was purchased from Analytical Sciences (Waltham, MA, USA). Fluorescent human amyloid beta-peptide (1–40)-Cy5 labeled ($\text{A}\beta_{1-40}\text{Cy5}$) was purchased from Phoenix Pharmaceuticals (Strasbourg, France). The powder was resuspended in $250\ \mu\text{L}$ of DMSO (Sigma-Aldrich, France) followed by an addition of $750\ \mu\text{L}$ of RH-HSA 0.1% to obtain a solution at $1\ \mu\text{M}$, according to the manufacturer's instructions, and stored at -20°C to be used at $10\ \text{nM}$ in RH-HSA 0.1% buffer. Receptor-associated protein (RAP Human, Recombinant, E.coli; 553506) was purchased from Merck Millipore, dissolved in RH-HSA 0.1%, and freshly used. Elacridar was purchased from Sigma-Aldrich (United Kingdom), dissolved in DMSO at $0.5\ \text{mM}$, and stored at -20°C to be used at $0.5\ \mu\text{M}$ in RH-HSA 0.1% buffer.

4.2. The Human in Vitro BBB Model

The human brain-like endothelial cells (BLECs) from the in vitro BBB model were from the co-culture of endothelial cells (ECs) derived from CD34^{+} cord blood hematopoietic stem cells with brain pericytes as previously described by Cecchelli et al. (2014) [38]. Donors' parents, in accordance with French legislation, gave their consent for the collection of human umbilical cord blood. The French Ministry of Higher Education and Research (CODECOH DC2011-1321) approved the collection of human cells. According to the method described by Pedroso et al. (2011) [86], CD34^{+} stem cells were isolated from human umbilical cord blood and then prompted to differentiate into ECs. For the differentiation step, isolated CD34^{+} were cultured in endothelial cell growth medium-2 (EGM-2; Lonza) supplemented with 20% (v/v) FCS (Life Technologies) and $50\ \text{ng}\cdot\text{mL}^{-1}$ of vascular endothelial growth factor (VEGF) (PreproTech Inc), on 0.2% gelatin-coated 24-well plates (2×10^5 cells/well). After 15–20 days of differentiation, ECs were amplified in the culture dish at P2 and frozen in frozen medium (10% DMSO, 50% FCS, ECM-5). Then, ECs were thawed and seeded onto Matrigel (BD Biosciences, San Jose, CA, USA)-coated filters (Costar Transwell inserts, Corning Inc., Corning, NY, USA, pore size $0.4\ \mu\text{m}$, 8×10^4 cells/insert), and co-cultured with bovine brain pericytes isolated as described by Vandenhoute et al. (2011) [87] in a 12-well plate with ECM-5. The culture medium was changed every two days. These culture conditions were maintained for 5 days and enabled the CD34^{+} -ECs to acquire a BBB phenotype (i.e., BLECs). Under these conditions, the model was ready for experiments and stable for 21 days. A mycoplasma detection (Lonza, Rockland, ME, USA) was performed to validate the absence of mycoplasma in the cell culture medium.

The co-culture model delimits two compartments, the apical compartment that mimics the blood side and the basolateral compartment that mimics the brain side. The BBB model was described in Cecchelli et al. (2014) [38].

4.3. Treatment with KBs

After 5 days of co-culture, AcAc and/or βHB were added to the apical compartment (blood side) for 48 h at 37°C . The concentrations used (5, 10, 15, and 20 mM AcAc or βHB or both in ratio 20 mM AcAc/20 mM βHB) were selected according to the KB levels measured during a normal diet (basal serum level $< 0.3\ \text{mM}$), a ketogenic diet or starvation (5–8 mM), and diabetic ketoacidosis ($> 25\ \text{mM}$) [58,88]. Since blood AcAc and βHB are normally present in the blood during fasting or starvation at a 1:1 ratio, we also treated cells with 20 mM AcAc/20 mM βHB [89]. The pH of the cell culture medium with or without KBs was measured during experimental conditions (48 h at 37°C and 5% CO_2) using a pH meter (WTW inolab pH level 1). In these conditions, the pH of the cell culture media was monitored before (~ 7.3) and after (~ 6.9) KB treatments. No significant pH variation was observed after KB treatment compared to the control.

4.4. Cell Viability Assay

Cell viability was determined using the standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (AR1156, Boster Biological Technology, Pleasanton, CA, USA). For each condition tested, cells were seeded in triplicate and incubated during 48 h in the absence or in the presence of different concentrations of KBs (5, 10, 15, 20 mM of each, or in ratio 20 mM AcAc/20 mM β HB) once the BBB phenotype was established. Following treatments, 150 000 BLECs/insert were counted for each condition. MTT was added to the apical compartment for 2 h at 37 °C and 5% CO₂, and the purple formazan crystals from MTT were then dissolved with DMSO (300 μ L/well). The optical density (OD) was measured at a wavelength of 570 and 630 nm using a microplate reader (Synergy H1, BioTek, Colmar, France). The % relative cell viability compared to the control condition was calculated using the following formula: % relative cell viability = ((OD₅₇₀ - OD₆₃₀) condition)/((OD₅₇₀ - OD₆₃₀) control) \times 100.

4.5. Measurement of glucose and β HB levels in culture medium

After 5 days of co-culture, 20 mM AcAc or 20 mM β HB or 20 mM AcAc/20mM β HB (ratio treatment) was added to the apical compartment for 48 h at 37 °C and 5% CO₂. During this time, the glucose and β HB concentrations were measured in both the apical compartment and the basolateral compartment. The Precision-Xtra meter (Abbott Labs, Abbott Park, IL, USA) with a glucose or β -ketone sticks was used. In these assays, the glucose and β HB concentrations measured by the sticks were representative of the glucose and β HB present in the culture medium. Data were expressed in mmol·L⁻¹ for β HB and in g·L⁻¹ for glucose. The β HB concentration within BLECs was measured at 48 h following the treatment. Briefly, after medium removal, BLECs were washed twice with RH buffer and lysed with RIPA lysis buffer (Millipore Corporation, Burlington, MA, USA). The β HB concentration in the BLECs was normalized by the protein amount using Bradford assay (Bio-rad, Munich, Germany). The amount of β HB into the supernatant was assayed using β -ketone sticks, as described above. The β HB concentration was verified in the culture medium without cells at 37 °C and 5% CO₂ to ensure the stability of β HB.

4.6. Evaluation of BLEC Monolayer Permeability

The integrity of the BLEC monolayer after 48 h of treatment with KBs was evaluated using the method described by Dehouck et al. (1992) [90]. Each coculture condition was performed in triplicate. The fluorescent integrity marker LY was used at a final concentration of 50 μ M in RH buffer to obtain the endothelial permeability coefficient (Pe) from the apical-to-basolateral compartment. The fluorescence of LY in each compartment was measured using the excitation/emission wavelength (432/538 nm) using a microplate reader (Synergy H1). In this calculation method, both the filter without cell permeability (PSf = insert filter + matrigel coating) and filter plus cell permeability (PSt = insert filter + matrigel coating + ECs) were taken into account, according to the formula: $1/PSe = 1/PSt + 1/PSf$, where PS is the permeability \times surface area product (in microliters per minute) obtained by dividing the volume cleared from the donor to the receiver compartment (in μ L) for 1 h. The mass balance (%) was calculated from the amount of compound recovered in the donor and receiver compartment at the end of the experiment divided by the total amount added in the donor compartment at time zero. To be taken into account for Pe determination, the mass balance should be between 80% and 120%.

4.7. Immunostaining

After 48 h of treatments with or without KBs, BLECs were fixed and permeabilized as described in Table 1. Then, a 30-min blocking with PBS-CMF (0.2 g·L⁻¹ KH₂PO₄, 8.0 g·L⁻¹ NaCl, 2.87 g·L⁻¹ Na₂HPO₄-12H₂O, and 0.2 g·L⁻¹ KCl) with 10% (v/v) normal goat serum (NGS) was performed. Then, cells were incubated for 60 min with the primary antibody in PBS-CMF supplemented with 2% NGS at room temperature (RT), against the target protein as described in Table 1.

Table 1. Antibodies used for the immunostaining experiment.

Protein Target	Antibody Reference	Fixation/Permeabilization	Antibody Dilution
Claudin-5	34-1600 (Invitrogen)	Ice-methanol 30''	1:100
GLUT1	07-1401 (Merck Millipore)	Ice-methanol 30''	1:100
MCT1	AB3538P (Merck Millipore)	Ice-methanol 30''	1:100
ZO1	61-7300 (Invitrogen)	Paraformaldehyde 1% 10'/ Triton X100 0,1% 10'	1:200

After three washes in PBS-CMF supplemented with 2% NGS, the cells were incubated with secondary polyclonal antibody (goat anti-rabbit Alexa 568, A11036, Molecular Probes, Eugene, OR, USA) diluted 1:500 in PBS-CMF supplemented with 2% NGS in the dark for 30 min at RT. Hoechst 33358 was used for nuclei staining. After mounting with Mowiol (Sigma-Aldrich) containing 1,4-diazabicyclo [2.2.2]octane (Sigma-Aldrich), images were taken using a Leica microscope (DMRD; Leica Microsystems, Wetzlar, Germany) and processed using ImageJ32 software.

4.8. Protein Extraction and Immunoblots

After 48 h of treatment, BLECs were washed twice with cold RH buffer and scraped with 50 μ L UT4 lysis buffer (7M Urea, 2M Thiourea, 4% CHAPS) or 50 μ L RIPA 1X lysis buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) (Merck Millipore, USA) supplemented with a cocktail of protease and phosphatase inhibitors purchased from Sigma-Aldrich (1% protease inhibitors cocktail P8340; 1% phosphatase inhibitors cocktail 1 P2850; 1% phosphatase inhibitors cocktail 2 P5726). Lysates were then centrifuged at 10,000 rpm for 10 min at 4 °C. The supernatant was saved and sonicated three times at 40 W for 5 s. The lysate protein concentration was measured using the Bradford method. Then, 30 μ g of total protein for LRP1 or 20 μ g for the other proteins were mixed with Laemmli (Bio-rad, Munich, Germany) supplemented with beta-mercaptoethanol (Sigma-Aldrich, Germany) and boiled for 5 min at 95 °C. Details of the denaturation and reduction step of the protein extract are described in Table 2.

Table 2. Antibodies used for the Western blot experiment.

Protein Target	Antibody Reference	Lysis Buffer	Special Condition	Antibody Dilution	Size (kDa)
β -actin	A5541 (Sigma Aldrich)	RIPA	-	1:20000	42
BCRP	Ab3380 (Abcam)	RIPA	Without heat denaturation	1:1000	72
GLUT1	07-1401 (Merck millipore)	RIPA	-	1:1000	55
LRP1	5A6 (Santa Cruz)	UT4	Without reduction/ β -mercaptoethanol	1:200	85
MCT1	Ab179832 (Abcam)	RIPA	-	1:1000	54
P-gp	C219 (Gene Tex)	RIPA	Without heat denaturation	1:500	180
PICALM	HPA019053 (Sigma Aldrich)	RIPA	-	1:1250	70
RAGE	Ab37647 (Abcam)	RIPA	-	1:1000	40

Then, the protein mixes were electrophoresed using Criterion™ TGX™ (Tris-Glycine eXtended) precast gels (Bio-rad) and subsequently electrotransferred to nitro cellulose membranes (GE Healthcare, Germany). Nonspecific binding sites were blocked by incubating the membrane with Tris-buffered saline 0.1% Tween 20 (TBST; 20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 0.1% Tween 20) supplemented with 5% skimmed milk at RT for 1 h under agitation. Membranes were incubated in the appropriate primary antibodies (Table 2) and incubated at 4 °C overnight, excepted for P-gp (2 h at RT) and β -actin (20 min at RT). Then, membranes were washed with TBST three times for 5 min each, and then incubated with the horseradish peroxidase conjugated secondary antibody anti-mouse (1:3000, Dako/Agilent Technologies, Inc., Santa Clara, CA, USA,) or secondary antibody anti-rabbit (1:8000, Dako/Agilent Technologies, Inc., Santa Clara, CA, USA) for 1 h at RT. Then, membranes were washed with TBST three

times for 5 min each and bands of immunoreactive protein were visualized after membrane incubation with enhanced chemiluminescence (GE Healthcare) reagent and revealed by the Western blot Imaging system Azure c600 (Azure Biosystems, Dublin, Ireland). Quantification of the relative densities of bands was performed with TotalLab TL 100 1D Gel Analysis software (Nonlinear Dynamics, Newcastle, UK). The protein expression normalization was conducted with anti- β -actin. Studies were performed at least three independent experiments, with two Western blots per experiment.

4.9. Amyloid- β (1-40) Peptide Transport Studies

Forty-eight hours after KB treatments, the apical-to-basolateral and the basolateral-to-apical transport of $A\beta_{1-40}$ across BLECs was investigated as previously described [13,44,46] (Briefly, for apical-to-basolateral studies, filters were transferred to new 12-well plates containing 1.5 mL of RH-HSA 0.1% (the receiver solution) per well. In the insert corresponding to the apical compartment, 0.5 mL of RH-HSA 0.1% supplemented with 10 nM $A\beta_{1-40}$ Cy5 peptide was added (the donor solution). For basolateral-to-apical studies, filters were transferred to 12-well plates containing 1.5 mL of RH-HSA 0.1% supplemented with 10 nM fluorescent $A\beta_{1-40}$ Cy5 (the donor solution). In the apical compartment, 0.5 mL of RH-HSA 0.1% (the receiver solution) was added. In parallel, the apical-to-basolateral and the basolateral-to-apical transport of 400 nM [3 H]inulin was performed in the same way as the $A\beta_{1-40}$ Cy5 peptide transport, thus representing a paracellular marker. The BBB integrity was checked by measuring the Pe_{LY} as described in Section 4.6. For LPR1 inhibition studies, the basolateral-to-apical transport of $A\beta_{1-40}$ transport was performed by adding 10 nM of $A\beta_{1-40}$ Cy5 peptide with or without 200 nM of RAP in the basolateral compartment. For P-gp inhibition studies, the basolateral-to-apical transport of $A\beta_{1-40}$ transport was performed by adding 10 nM of $A\beta_{1-40}$ Cy5 in the basolateral compartment with or without 0.5 μ M of elacridar in the apical compartment. All transport studies were performed in triplicate on a rocking platform at 37 °C for 30 min. At the end of the incubation period, aliquots of the donor and receiver solutions were collected, and the fluorescence compounds ($A\beta_{1-40}$ Cy5 and LY) were measured with a spectrofluorimeter (Synergy H1). The radioactivity of [3 H]inulin was measured using a scintillation counter (Hidex 300 SL, Hidex, Turku, Finland). The permeability (apparent permeability coefficient, $cm \cdot sec^{-1}$) of $A\beta_{1-40}$ -Cy5 or [3 H]-inulin was calculated according to the following equation: (1) $P_{app} = (k \cdot V(R)) / (A \cdot 60)$ as previously described [91]. k was the transport rate (min^{-1}) defined as the slope obtained by linear regression of the cumulative fraction absorbed (FACum) as a function of time (min), $V(R)$ was the volume in the receiver chamber (mL), and A was the area of the filter (cm^2). Determination of the cumulative fraction absorbed (amount permeated), FACum versus time, FACum was calculated from: (2) $FACum = \sum (C(Ri)) / (C(Di))$, where $C(Ri)$ was the receiver concentration at the end of the interval i and $C(Di)$ was the donor concentration at the beginning of interval i . A linear relationship should be obtained. The apical-to-basolateral and the basolateral-to-apical P_{app} were determined by Equation (1) for each molecule. For each filter, the calculated mass balance was determined as described in Section 4.6. Experiments were performed at least 3 times.

4.10. Statistical Analysis

All statistical analyses were performed using the GraphPad Prism 5.01 statistical software package (GraphPad Software, Inc., San Diego, CA, USA). Data are presented as the mean \pm standard error of the mean (SEM). The results of experiments were evaluated using the Mann Whitney t-test. The threshold for statistical significant was set to * $p < 0.05$, ** $p < 0.01$, or *** $p < 0.001$.

Author Contributions: Data curation, R.V. and M.C.; Formal analysis, R.V. and M.C.; Funding acquisition, A.F., R.B., F.G., L.F. and P.C.; Investigation, R.V. and M.C.; Methodology, R.V. and P.C.; Software, R.V. and E.S.; Supervision, R.B., F.G., L.F. and P.C.; Validation, R.V., M.C., A.F., E.S. and R.B.; Writing—original draft, P.C.; Writing—review & editing, A.F., R.B., F.G., L.F. and P.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by a grant from Artois University (the BQR-Ketodiet, Pietra Candela) and Sapienza University of Rome (Ateneo 2014 and 2017). Romain Versele received a doctoral fellowship from Artois

University (2017–2020). Mariangela Corsi received a doctoral fellowship from Sapienza University and from the Italian Foreign Ministry (via the French embassy in Italy) for 2015 and 2016.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

Aa	Amino acid
AcAc	Acetoacetate
AD	Alzheimer's disease
A β	Amyloid β
BBB	Blood-brain barrier
BCRP	Breast cancer resistance protein
β HB	β -hydroxybutyrate
BLECs	Brain-like endothelial cells
CNS	Central nervous system
DMSO	Dimethyl sulfoxide
ECM	Endothelial cell medium
EGM-2	Endothelial cell growth medium-2
FCS	Foetal calf serum
GLUT1	Glucose transporter 1
HSA	Human serum albumin
KBs	Ketone bodies
KD	Ketogenic diet
LRP1	Low-density lipoprotein receptor-related protein 1
LY	Lucifer yellow
MCT1	Monocarboxylate transporter 1
NGS	Normal goat serum
Pe	Endothelial permeability
PBS-CMF	Phosphate-buffered saline calcium- and magnesium-free
P-gp	P-glycoprotein
RAGE	Receptor for advanced glycation endproducts
RAP	Receptor-associated protein
RH	Ringer-HEPES
RT	Room temperature
SEM	Standard error of the mean
TBST	Tris-buffered saline 0.1% Tween 20
ZO-1	Zonula occludens-1

References

1. Castellani, R.J.; Perry, G. Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. *J. Alzheimers Dis.* **2019**, *67*, 447–467. [[CrossRef](#)]
2. Selkoe, D.J. Alzheimer's disease. *Cold Spring Harb. Perspect. Biol.* **2011**, *3*, a004457. [[CrossRef](#)]
3. Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. *Biochem. Biophys. Res. Commun.* **2012**, *425*, 534–539. [[CrossRef](#)]
4. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat. Rev. Neurosci.* **2011**, *12*, 723–738. [[CrossRef](#)]
5. Gosselet, F.; Saint-Pol, J.; Candela, P.; Fenart, L. Amyloid-beta Peptides, Alzheimer's Disease and the Blood-brain Barrier. *Curr. Alzheimer Res.* **2013**, *10*, 1015–1033. [[CrossRef](#)] [[PubMed](#)]
6. Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* **2010**, *330*, 1774. [[CrossRef](#)] [[PubMed](#)]
7. Gosselet, F.; Saint-Pol, J.; Fenart, L. Effects of oxysterols on the blood-brain barrier: Implications for Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **2014**, *446*, 687–691. [[CrossRef](#)] [[PubMed](#)]

8. Cecchelli, R.; Berezowski, V.; Lundquist, S.; Culot, M.; Renftel, M.; Dehouck, M.P.; Fenart, L. Modelling of the blood-brain barrier in drug discovery and development. *Nat. Rev. Drug Discov.* **2007**, *6*, 650–661. [[CrossRef](#)] [[PubMed](#)]
9. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. *Neurobiol. Dis.* **2010**, *37*, 13–25. [[CrossRef](#)]
10. Bell, R.D.; Sagare, A.P.; Friedman, A.E.; Bedi, G.S.; Holtzman, D.M.; Deane, R.; Zlokovic, B.V. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. *J. Cereb. Blood Flow Metab.* **2007**, *27*, 909–918. [[CrossRef](#)]
11. Shibata, M.; Yamada, S.; Kumar, S.R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.M.; Miller, C.A.; Strickland, D.K.; Ghiso, J.; et al. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J. Clin. Invest.* **2000**, *106*, 1489–1499. [[CrossRef](#)] [[PubMed](#)]
12. Deane, R.; Singh, I.; Sagare, A.P.; Bell, R.D.; Ross, N.T.; LaRue, B.; Love, R.; Perry, S.; Paquette, N.; Deane, R.J.; et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. *J. Clin. Invest.* **2012**, *122*, 1377–1392. [[CrossRef](#)] [[PubMed](#)]
13. Candela, P.; Gosselet, F.; Saint-Pol, J.; Sevin, E.; Boucau, M.C.; Boulanger, E.; Cecchelli, R.; Fenart, L. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. *J. Alzheimers Dis* **2010**, *22*, 849–859. [[CrossRef](#)] [[PubMed](#)]
14. Tai, L.M.; Loughlin, A.J.; Male, D.K.; Romero, I.A. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. *J. Cereb. Blood Flow. Metab.* **2009**, *29*, 1079–1083. [[CrossRef](#)] [[PubMed](#)]
15. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. *Neuron* **2008**, *57*, 178–201. [[CrossRef](#)]
16. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. *J. Clin. Invest.* **2005**, *115*, 3285–3290. [[CrossRef](#)]
17. Storck, S.E.; Hartz, A.M.S.; Bernard, J.; Wolf, A.; Kachlmeier, A.; Mahringer, A.; Weggen, S.; Pahnke, J.; Pietrzik, C.U. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. *Brain Behav. Immun.* **2018**, *73*, 21–33. [[CrossRef](#)]
18. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M.L.; Pahwa, J.S.; Moskvin, V.; Dowzell, K.; Williams, A.; et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. *Nat. Genet.* **2009**, *41*, 1088–1093. [[CrossRef](#)]
19. Xu, W.; Tan, L.; Wang, H.F.; Jiang, T.; Tan, M.S.; Tan, L.; Zhao, Q.F.; Li, J.Q.; Wang, J.; Yu, J.T. Meta-analysis of modifiable risk factors for Alzheimer’s disease. *J. Neurol. Neurosurg. Psych.* **2015**, *86*, 1299–1306. [[CrossRef](#)]
20. Bomben, V.; Holth, J.; Reed, J.; Cramer, P.; Landreth, G.; Noebels, J. Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. *Neurobiol. Aging* **2014**, *35*, 2091–2095. [[CrossRef](#)]
21. Ota, M.; Matsuo, J.; Ishida, I.; Takano, H.; Yokoi, Y.; Hori, H.; Yoshida, S.; Ashida, K.; Nakamura, K.; Takahashi, T.; et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer’s disease. *Neurosci. Lett.* **2019**, *690*, 232–236. [[CrossRef](#)] [[PubMed](#)]
22. Baranano, K.W.; Hartman, A.L. The ketogenic diet: uses in epilepsy and other neurologic illnesses. *Curr. Treat Options Neurol.* **2008**, *10*, 410–419. [[CrossRef](#)] [[PubMed](#)]
23. Paleologou, E.; Ismayilova, N.; Kinali, M. Use of the Ketogenic Diet to Treat Intractable Epilepsy in Mitochondrial Disorders. *J. Clin. Med.* **2017**, *6*, 56. [[CrossRef](#)] [[PubMed](#)]
24. Pawlosky, R.J.; Kemper, M.F.; Kashiwaya, Y.; King, M.T.; Mattson, M.P.; Veech, R.L. Effects of a dietary ketone ester on hippocampal glycolytic and tricarboxylic acid cycle intermediates and amino acids in a 3xTgAD mouse model of Alzheimer’s disease. *J. Neurochem.* **2017**, *141*, 195–207. [[CrossRef](#)]
25. Branco, A.F.; Ferreira, A.; Simoes, R.F.; Magalhaes-Novais, S.; Zehowski, C.; Cope, E.; Silva, A.M.; Pereira, D.; Sardao, V.A.; Cunha-Oliveira, T. Ketogenic diets: from cancer to mitochondrial diseases and beyond. *Eur. J. Clin. Invest.* **2016**, *46*, 285–298. [[CrossRef](#)]
26. Robinson, A.M.; Williamson, D.H. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. *Physiol. Rev.* **1980**, *60*, 143–187. [[CrossRef](#)]

27. Wlodarek, D. Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). *Nutrients* **2019**, *11*, 169. [[CrossRef](#)]
28. Morris, A.A. Cerebral ketone body metabolism. *J. Inherit. Metab. Dis.* **2005**, *28*, 109–121. [[CrossRef](#)]
29. Puchalska, P.; Crawford, P.A. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. *Cell Metab.* **2017**, *25*, 262–284. [[CrossRef](#)]
30. Cunnane, S.; Nugent, S.; Roy, M.; Courchesne-Loyer, A.; Croteau, E.; Tremblay, S.; Castellano, A.; Pifferi, F.; Bocti, C.; Paquet, N.; et al. Brain fuel metabolism, aging, and Alzheimer's disease. *Nutrition* **2011**, *27*, 3–20. [[CrossRef](#)]
31. Seyfried, T.N.; Mukherjee, P. Targeting energy metabolism in brain cancer: review and hypothesis. *Nutr. Metab.* **2005**, *2*, 30. [[CrossRef](#)] [[PubMed](#)]
32. Gasior, M.; Rogawski, M.A.; Hartman, A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. *Behav. Pharmacol.* **2006**, *17*, 431–439. [[CrossRef](#)] [[PubMed](#)]
33. Kashiwaya, Y.; Bergman, C.; Lee, J.H.; Wan, R.; King, M.T.; Mughal, M.R.; Okun, E.; Clarke, K.; Mattson, M.P.; Veech, R.L. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. *Neurobiol. Aging* **2013**, *34*, 1530–1539. [[CrossRef](#)] [[PubMed](#)]
34. Stafstrom, C.E.; Rho, J.M. The ketogenic diet as a treatment paradigm for diverse neurological disorders. *Front. Pharmacol.* **2012**, *3*, 59. [[CrossRef](#)]
35. Ari, C.; Kovacs, Z.; Juhasz, G.; Murdun, C.; Goldhagen, C.R.; Koutnik, A.P.; Poff, A.M.; Kesl, S.L.; D'Agostino, D.P. Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk Rats. *Front. Mol. Neurosci.* **2016**, *9*, 137. [[CrossRef](#)] [[PubMed](#)]
36. Van der Auwera, I.; Wera, S.; Van Leuven, F.; Henderson, S.T. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. *Nutr. Metab.* **2005**, *2*, 28. [[CrossRef](#)] [[PubMed](#)]
37. Yin, J.X.; Maalouf, M.; Han, P.; Zhao, M.; Gao, M.; Dharshaun, T.; Ryan, C.; Whitelegge, J.; Wu, J.; Eisenberg, D.; et al. Ketones block amyloid entry and improve cognition in an Alzheimer's model. *Neurobiol. Aging* **2016**, *39*, 25–37. [[CrossRef](#)]
38. Cecchelli, R.; Aday, S.; Sevin, E.; Almeida, C.; Culot, M.; Dehouck, L.; Coisne, C.; Engelhardt, B.; Dehouck, M.P.; Ferreira, L. A Stable and Reproducible Human Blood-Brain Barrier Model Derived from Hematopoietic Stem Cells. *PLoS ONE* **2014**, *9*, e99733. [[CrossRef](#)]
39. Kuntz, M.; Candela, P.; Saint-Pol, J.; Lamartiniere, Y.; Boucau, M.C.; Sevin, E.; Fenart, L.; Gosselet, F. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-beta Peptides in an In Vitro Model of the Human Blood-Brain Barrier. *J. Alzheimers Dis.* **2015**, *48*, 849–862. [[CrossRef](#)]
40. Praca, C.; Rai, A.; Santos, T.; Cristovao, A.C.; Pinho, S.L.; Cecchelli, R.; Dehouck, M.P.; Bernardino, L.; Ferreira, L.S. A nanoformulation for the preferential accumulation in adult neurogenic niches. *J. Control. Release* **2018**, *284*, 57–72. [[CrossRef](#)]
41. Cornford, E.M.; Hyman, S.; Black, K.L.; Cornford, M.E.; Vinters, H.V.; Pardridge, W.M. High expression of the Glut1 glucose transporter in human brain hemangioblastoma endothelium. *J. Neuropathol. Exp. Neurol.* **1995**, *54*, 842–851. [[CrossRef](#)] [[PubMed](#)]
42. Cortes-Campos, C.; Elizondo, R.; Llanos, P.; Uranga, R.M.; Nualart, F.; Garcia, M.A. MCT expression and lactate influx/efflux in tanycytes involved in glia-neuron metabolic interaction. *PLoS ONE* **2011**, *6*, e16411. [[CrossRef](#)] [[PubMed](#)]
43. Ramanathan, A.; Nelson, A.R.; Sagare, A.P.; Zlokovic, B.V. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1. *Front. Aging Neurosci.* **2015**, *7*, 136. [[CrossRef](#)] [[PubMed](#)]
44. Candela, P.; Saint-Pol, J.; Kuntz, M.; Boucau, M.C.; Lamartiniere, Y.; Gosselet, F.; Fenart, L. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes. *Brain Res.* **2015**, *1594*, 15–26. [[CrossRef](#)] [[PubMed](#)]
45. Zlokovic, B.V.; Martel, C.L.; Matsubara, E.; McComb, J.G.; Zheng, G.; McCluskey, R.T.; Frangione, B.; Ghiso, J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 4229–4234. [[CrossRef](#)] [[PubMed](#)]

46. Saint-Pol, J.; Candela, P.; Boucau, M.C.; Fenart, L.; Gosselet, F. Oxysterols decrease apical-to-basolateral transport of Abeta peptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells. *Brain Res.* **2013**, *1517*, 1–15. [[CrossRef](#)]
47. Storck, S.E.; Meister, S.; Nahrath, J.; Meissner, J.N.; Schubert, N.; Di Spiezio, A.; Baches, S.; Vandenbroucke, R.E.; Bouter, Y.; Prikulis, I.; et al. Endothelial LRP1 transports amyloid-beta(1-42) across the blood-brain barrier. *J. Clin. Invest.* **2016**, *126*, 123–136. [[CrossRef](#)]
48. Gameiro, M.; Silva, R.; Rocha-Pereira, C.; Carmo, H.; Carvalho, F.; Bastos, M.L.; Remiao, F. Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP. *Molecules* **2017**, *22*. [[CrossRef](#)]
49. Andersen, O.M.; Christensen, L.L.; Christensen, P.A.; Sorensen, E.S.; Jacobsen, C.; Moestrup, S.K.; Etzerodt, M.; Thogersen, H.C. Identification of the minimal functional unit in the low density lipoprotein receptor-related protein for binding the receptor-associated protein (RAP). A conserved acidic residue in the complement-type repeats is important for recognition of RAP. *J. Biol. Chem.* **2000**, *275*, 21017–21024. [[CrossRef](#)]
50. Deane, R.; Wu, Z.; Sagare, A.; Davis, J.; Du Yan, S.; Hamm, K.; Xu, F.; Parisi, M.; LaRue, B.; Hu, H.W.; et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. *Neuron* **2004**, *43*, 333–344. [[CrossRef](#)]
51. Deane, R.; Sagare, A.; Zlokovic, B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. *Curr. Pharm. Des.* **2008**, *14*, 1601–1605. [[CrossRef](#)] [[PubMed](#)]
52. Jedlitschky, G.; Grube, M.; Mosyagin, I.; Kroemer, H.K.; Vogelgesang, S. Targeting CNS transporters for treatment of neurodegenerative diseases. *Curr. Pharm. Des.* **2014**, *20*, 1523–1533. [[CrossRef](#)] [[PubMed](#)]
53. Hertz, L.; Chen, Y.; Waagepetersen, H.S. Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, beta-amyloid toxicity, and astrocyte function. *J. Neurochem.* **2015**, *134*, 7–20. [[CrossRef](#)] [[PubMed](#)]
54. Reger, M.A.; Henderson, S.T.; Hale, C.; Cholerton, B.; Baker, L.D.; Watson, G.S.; Hyde, K.; Chapman, D.; Craft, S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. *Neurobiol. Aging* **2004**, *25*, 311–314. [[CrossRef](#)]
55. Kong, G.; Huang, Z.; Ji, W.; Wang, X.; Liu, J.; Wu, X.; Huang, Z.; Li, R.; Zhu, Q. The Ketone Metabolite beta-Hydroxybutyrate Attenuates Oxidative Stress in Spinal Cord Injury by Suppression of Class I Histone Deacetylases. *J. Neurotrauma* **2017**, *34*, 2645–2655. [[CrossRef](#)] [[PubMed](#)]
56. Isales, C.M.; Min, L.; Hoffman, W.H. Acetoacetate and beta-hydroxybutyrate differentially regulate endothelin-1 and vascular endothelial growth factor in mouse brain microvascular endothelial cells. *J. Diabetes Complications* **1999**, *13*, 91–97. [[CrossRef](#)]
57. Mullin, G.E. Issues in complementary and alternative nutrition treatments. *Nutr. Clin. Pract.* **2009**, *24*, 543–548. [[CrossRef](#)]
58. Hashim, S.A.; VanItallie, T.B. Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester. *J. Lipid Res.* **2014**, *55*, 1818–1826. [[CrossRef](#)]
59. Ballaban-Gil, K.; Callahan, C.; O'Dell, C.; Pappo, M.; Moshe, S.; Shinnar, S. Complications of the ketogenic diet. *Epilepsia* **1998**, *39*, 744–748. [[CrossRef](#)]
60. Wood, T.R.; Stubbs, B.J.; Juul, S.E. Exogenous Ketone Bodies as Promising Neuroprotective Agents for Developmental Brain Injury. *Dev. Neurosci.* **2018**, *40*, 451–462. [[CrossRef](#)]
61. Henderson, S.T.; Vogel, J.L.; Barr, L.J.; Garvin, F.; Jones, J.J.; Costantini, L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. *Nutr. Metab.* **2009**, *6*, 31. [[CrossRef](#)] [[PubMed](#)]
62. D'Agostino, D.P.; Pilla, R.; Held, H.E.; Landon, C.S.; Puchowicz, M.; Brunengraber, H.; Ari, C.; Arnold, P.; Dean, J.B. Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2013**, *304*, R829–R836. [[CrossRef](#)] [[PubMed](#)]
63. Stubbs, B.J.; Cox, P.J.; Evans, R.D.; Santer, P.; Miller, J.J.; Faull, O.K.; Magor-Elliott, S.; Hiyama, S.; Stirling, M.; Clarke, K. On the Metabolism of Exogenous Ketones in Humans. *Front. Physiol.* **2017**, *8*, 848. [[CrossRef](#)] [[PubMed](#)]
64. Vannucci, S.J.; Simpson, I.A. Developmental switch in brain nutrient transporter expression in the rat. *Am. J. Physiol. Endocrinol. Metab.* **2003**, *285*, E1127–E1134. [[CrossRef](#)]
65. Leino, R.L.; Gerhart, D.Z.; Duelli, R.; Enerson, B.E.; Drewes, L.R. Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. *Neurochem. Int.* **2001**, *38*, 519–527. [[CrossRef](#)]

66. Puchowicz, M.A.; Xu, K.; Sun, X.; Ivy, A.; Emancipator, D.; LaManna, J.C. Diet-induced ketosis increases capillary density without altered blood flow in rat brain. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *292*, E1607–E1615. [[CrossRef](#)]
67. Ma, D.; Wang, A.C.; Parikh, I.; Green, S.J.; Hoffman, J.D.; Chlipala, G.; Murphy, M.P.; Sokola, B.S.; Bauer, B.; Hartz, A.M.S.; et al. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. *Sci. Rep.* **2018**, *8*, 6670. [[CrossRef](#)]
68. Pifferi, F.; Tremblay, S.; Croteau, E.; Fortier, M.; Tremblay-Mercier, J.; Lecomte, R.; Cunnane, S.C. Mild experimental ketosis increases brain uptake of ¹¹C-acetoacetate and ¹⁸F-fluorodeoxyglucose: a dual-tracer PET imaging study in rats. *Nutr. Neurosci.* **2011**, *14*, 51–58. [[CrossRef](#)]
69. Tanegashima, K.; Sato-Miyata, Y.; Funakoshi, M.; Nishito, Y.; Aigaki, T.; Hara, T. Epigenetic regulation of the glucose transporter gene *Slc2a1* by beta-hydroxybutyrate underlies preferential glucose supply to the brain of fasted mice. *Genes Cells* **2017**, *22*, 71–83. [[CrossRef](#)]
70. Studzinski, C.M.; MacKay, W.A.; Beckett, T.L.; Henderson, S.T.; Murphy, M.P.; Sullivan, P.G.; Burnham, W.M. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. *Brain Res.* **2008**, *1226*, 209–217. [[CrossRef](#)]
71. Gillette-Guyonnet, S.; Secher, M.; Vellas, B. Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. *Br. J. Clin. Pharmacol.* **2013**, *75*, 738–755. [[CrossRef](#)] [[PubMed](#)]
72. Hu, N.; Yu, J.T.; Tan, L.; Wang, Y.L.; Sun, L.; Tan, L. Nutrition and the risk of Alzheimer's disease. *BioMed Res. Int.* **2013**, *2013*, 524820. [[CrossRef](#)] [[PubMed](#)]
73. Fuso, A.; Nicolia, V.; Cavallaro, R.A.; Ricceri, L.; D'Anselmi, F.; Coluccia, P.; Calamandrei, G.; Scarpa, S. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. *Mol. Cell Neurosci.* **2008**, *37*, 731–746. [[CrossRef](#)] [[PubMed](#)]
74. Qosa, H.; Batarseh, Y.S.; Mohyeldin, M.M.; El Sayed, K.A.; Keller, J.N.; Kaddoumi, A. Oleocanthal Enhances Amyloid-beta Clearance from the Brains of TgSwDI Mice and in Vitro across a Human Blood-Brain Barrier Model. *ACS Chem. Neurosci.* **2015**, *6*, 1849–1859. [[CrossRef](#)]
75. Qosa, H.; Abuznait, A.H.; Hill, R.A.; Kaddoumi, A. Enhanced Brain Amyloid-beta Clearance by Rifampicin and Caffeine as a Possible Protective Mechanism Against Alzheimer's Disease. *J. Alzheimers Dis.* **2012**, *31*, 151–165. [[CrossRef](#)]
76. Deane, R.; Du Yan, S.; Subramanian, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. *Nat. Med.* **2003**, *9*, 907–913. [[CrossRef](#)]
77. Zhao, Z.; Nelson, A.R.; Betsholtz, C.; Zlokovic, B.V. Establishment and Dysfunction of the Blood-Brain Barrier. *Cell* **2015**, *163*, 1064–1078. [[CrossRef](#)]
78. Do, T.M.; Noel-Hudson, M.S.; Ribes, S.; Besengez, C.; Smirnova, M.; Cisternino, S.; Buyse, M.; Calon, F.; Chimini, G.; Chacun, H.; et al. ABCG2- and ABCG4-mediated efflux of amyloid-beta peptide 1-40 at the mouse blood-brain barrier. *J. Alzheimers Dis.* **2012**, *30*, 155–166. [[CrossRef](#)]
79. Krohn, M.; Lange, C.; Hofrichter, J.; Scheffler, K.; Stenzel, J.; Steffen, J.; Schumacher, T.; Bruning, T.; Plath, A.S.; Alfen, F.; et al. Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. *J. Clin. Invest.* **2011**, *121*, 3924–3931. [[CrossRef](#)]
80. Guo, Y.X.; He, L.Y.; Zhang, M.; Wang, F.; Liu, F.; Peng, W.X. 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Abeta1-40 brain-to-blood efflux and peripheral uptake transport. *Neuroscience* **2016**, *322*, 28–38. [[CrossRef](#)]
81. Cheng, S.; Wu, Q.; Yang, F.; Xu, M.; Leski, M.; Chen, G.Q. Influence of DL-beta-hydroxybutyric acid on cell proliferation and calcium influx. *Biomacromolecules* **2005**, *6*, 593–597. [[CrossRef](#)] [[PubMed](#)]
82. Kanikarla-Marie, P.; Jain, S.K. Hyperketonemia (acetoacetate) upregulates NADPH oxidase 4 and elevates oxidative stress, ICAM-1, and monocyte adhesivity in endothelial cells. *Cell Physiol. Biochem.* **2015**, *35*, 364–373. [[CrossRef](#)] [[PubMed](#)]
83. Jain, S.K.; Kannan, K.; Lim, G.; McVie, R.; Bocchini, J.A., Jr. Hyperketonemia increases tumor necrosis factor-alpha secretion in cultured U937 monocytes and Type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency. *Diabetes* **2002**, *51*, 2287–2293. [[CrossRef](#)] [[PubMed](#)]
84. Anderson, O.S.; Sant, K.E.; Dolinoy, D.C. Nutrition and epigenetics: An interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. *J. Nutr. Biochem.* **2012**, *23*, 853–859. [[CrossRef](#)] [[PubMed](#)]

85. Newman, J.C.; Verdin, E. β -Hydroxybutyrate: A Signaling Metabolite. *Annu. Rev. Nutr.* **2017**, *37*, 51–76. [[CrossRef](#)]
86. Pedroso, D.C.; Tellechea, A.; Moura, L.; Fidalgo-Carvalho, I.; Duarte, J.; Carvalho, E.; Ferreira, L. Improved survival, vascular differentiation and wound healing potential of stem cells co-cultured with endothelial cells. *PLoS ONE* **2011**, *6*, e16114. [[CrossRef](#)]
87. Vandenhoute, E.; Dehouck, L.; Boucau, M.C.; Sevin, E.; Uzbekov, R.; Tardivel, M.; Gosselet, F.; Fenart, L.; Cecchelli, R.; Dehouck, M.P. Modelling the neurovascular unit and the blood-brain barrier with the unique function of pericytes. *Curr. Neurovasc. Res.* **2011**, *8*, 258–269. [[CrossRef](#)]
88. Paoli, A.; Bosco, G.; Camporesi, E.M.; Mangar, D. Ketosis, ketogenic diet and food intake control: a complex relationship. *Front. Psych.* **2015**, *6*, 27. [[CrossRef](#)]
89. Laffel, L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. *Diabetes Metab. Res. Rev.* **1999**, *15*, 412–426. [[CrossRef](#)]
90. Dehouck, M.P.; Jolliet-Riant, P.; Bree, F.; Fruchart, J.C.; Cecchelli, R.; Tillement, J.P. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. *J. Neurochem.* **1992**, *58*, 1790–1797. [[CrossRef](#)]
91. Sevin, E.; Dehouck, L.; Fabulas-da Costa, A.; Cecchelli, R.; Dehouck, M.P.; Lundquist, S.; Culot, M. Accelerated Caco-2 cell permeability model for drug discovery. *J. Pharmacol. Toxicol. Methods* **2013**, *68*, 334–339. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).